check_circleStudy Completed
Prostatic Neoplasms
Bayer Identifier:
16506
ClinicalTrials.gov Identifier:
EudraCT Number:
EU CT Number:
Not Available
Re-treatment safety of radium-223 dichloride in castration-resistant prostate cancer with bone metastases
Trial purpose
Eligible subjects must have completed 6 doses of treatment of radium-223 dichloride and experienced no radium-223 dichloride-related SAEs (serious adverse events) or CTCAE (Common Terminology Criteria for Adverse Events) Grade 3 or 4 adverse event during or after the initial course of radium-223 dichloride that led to the discontinuation of treatment. 40 Subjects will be enrolled and will receive up to 6 doses of radium-223 dichloride 50 kBq/kg IV every 4 weeks.
The subject will be evaluated for AEs (adverse events) and laboratory tests at each visit every 4 weeks, prior to receiving radium-223 dichloride.
After the end of treatment visit the subjects will enter the active follow up period. Related AEs and SAEs and Lab tests will be evaluated at each visit every 4 weeks for the first 12 weeks, then every 12 weeks for up to 2 years after the last dose of radium-223 dichloride.
After the 2 years of active follow-up, subjects will enter the long-term follow-up period and will be followed via telephone follow-up at 6-month intervals for late toxicities and survival up to 7 years after the last dose of radium-223 dichloride or until death.
Joint safety reviews will regularly take place to oversee safety of the subjects conducted at regular intervals.
An interim analysis of the safety data will be conducted during the study.
The subject will be evaluated for AEs (adverse events) and laboratory tests at each visit every 4 weeks, prior to receiving radium-223 dichloride.
After the end of treatment visit the subjects will enter the active follow up period. Related AEs and SAEs and Lab tests will be evaluated at each visit every 4 weeks for the first 12 weeks, then every 12 weeks for up to 2 years after the last dose of radium-223 dichloride.
After the 2 years of active follow-up, subjects will enter the long-term follow-up period and will be followed via telephone follow-up at 6-month intervals for late toxicities and survival up to 7 years after the last dose of radium-223 dichloride or until death.
Joint safety reviews will regularly take place to oversee safety of the subjects conducted at regular intervals.
An interim analysis of the safety data will be conducted during the study.
Key Participants Requirements
Sex
MaleAge
18 - N/ATrial summary
Enrollment Goal
45Trial Dates
December 2013 - April 2017Phase
Phase 1/Phase 2Could I Receive a placebo
NoProducts
Xofigo (Radium-223 dichloride, BAY88-8223)Accepts Healthy Volunteer
NoWhere to participate
Status | Institution | Location |
---|---|---|
Withdrawn | Galway, Ireland | |
Withdrawn | Cork, Ireland | |
Completed | Jerusalem, 9112001, Israel | |
Completed | Kfar Saba, 4428164, Israel | |
Completed | Haifa, 3109601, Israel | |
Completed | New Orleans, 70112, United States | |
Withdrawn | Stockholm, 171 76, Sweden | |
Withdrawn | Ålesund, 6026, Norway | |
Completed | Bergen, 5021, Norway | |
Completed | Lørenskog, 1478, Norway | |
Completed | Umeå, 901 85, Sweden | |
Completed | Kuopio, 70210, Finland | |
Withdrawn | Seinäjoki, FIN 60220, Finland | |
Withdrawn | Tampere, 33521, Finland | |
Completed | Málaga, 29010, Spain | |
Completed | Córdoba, 14004, Spain | |
Completed | Barcelona, 08025, Spain | |
Completed | Milano, 20133, Italy | |
Completed | Forlì-Cesena, 47014, Italy | |
Withdrawn | Genova, 16128, Italy | |
Withdrawn | Los Angeles, 90033, United States | |
Withdrawn | Los Angeles, 90033, United States | |
Withdrawn | Rostock, 18107, Germany | |
Withdrawn | München, 81675, Germany | |
Withdrawn | Dresden, 01307, Germany | |
Withdrawn | Nottingham, NG5 1PB, United Kingdom | |
Withdrawn | Belfast, BT9 7AB, United Kingdom | |
Completed | Petah Tikva, 4941492, Israel | |
Completed | Omaha, 68130, United States | |
Withdrawn | Stanford, 94305, United States | |
Completed | Syracuse, 13210, United States | |
Withdrawn | Charlotte, 28203, United States | |
Withdrawn | Aachen, 52074, Germany |
Primary Outcome
- Number of participants with treatment-emergent adverse events (AEs)An adverse event (AE) is any untoward medical occurrence (i.e., any unfavorable and unintended sign [including abnormal laboratory findings], symptom, or disease) in a participant or clinical investigation participant after providing written informed consent for participation in the study. A treatment-emergent adverse events (TEAE) is defined as any event arising or worsening after the start of study drug administration until 30 days after the last administration of radium-223 dichloride.date_rangeTime Frame:Up to 2.5 yearsenhanced_encryptionYesSafety Issue:
- Number of participants with treatment-emergent serious adverse events (SAEs)TESAE occurred after the start of radium-223 dichloride treatment until 30 days after the last dose and results in death; is life-threatening; requires inpatient hospitalization or prolongs existing hospitalization; results in persistent or significant disability or incapacity; is a congenital anomaly / birth defect; is another medically important serious event as judged by the investigator; or is an occurrence of leukemia, myelodysplastic syndrome, aplastic anemia, myelofibrosis, and primary bone cancer or any other new primary malignancy, such as acute myeloid leukemia.date_rangeTime Frame:Up to 2.5 yearsenhanced_encryptionYesSafety Issue:
- Number of participants with Radium-223 dichloride-related AEs in the active follow-up periodAn adverse event (AE) is any untoward medical occurrence (i.e., any unfavorable and unintended sign [including abnormal laboratory findings], symptom, or disease) in a participant or clinical investigation participant after providing written informed consent for participation in the study.date_rangeTime Frame:Up to 2 years after last treatmentenhanced_encryptionYesSafety Issue:
- Number of participants with Radium-223 dichloride-related SAEs in the active follow-up periodTreatment-related SAE is any SAE that, according to the investigator’s causality assessment, is possibly or probably related to treatment with radium-223 dichloride.date_rangeTime Frame:Up to 2 years after last treatmentenhanced_encryptionYesSafety Issue:
- Number of participants with high/low abnormalities in hematology variables at any visit after treatment startdate_rangeTime Frame:Up to 2.5 yearsenhanced_encryptionYesSafety Issue:
- Number of participants with high/low abnormalities in biochemistry variables at any visit after treatment startdate_rangeTime Frame:Up to 2.5 yearsenhanced_encryptionYesSafety Issue:
- Number of participants who discontinued Radium-223 dichloride treatment due to treatment emergent AEs or deathAn adverse event (AE) is any untoward medical occurrence (i.e., any unfavorable and unintended sign [including abnormal laboratory findings], symptom, or disease) in a participant or clinical investigation participant after providing written informed consent for participation in the study. A treatment-emergent adverse events (TEAE) is defined as any event arising or worsening after the start of study drug administration until 30 days after the last administration of radium-223 dichloride.date_rangeTime Frame:Up to 2.5 yearsenhanced_encryptionYesSafety Issue:
Trial design
Trial Type
InterventionalIntervention Type
DrugTrial Purpose
TreatmentAllocation
N/ABlinding
Open LabelAssignment
Single Group AssignmentTrial Arms
1Additional Information
Click here and search for drug information provided by the FDA.Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.Click here to find results for studies related to Bayer Healthcare products.Click here to find information about studies related to Bayer Healthcare products conducted in Europe.